Dechra Pharmaceuticals PLC Trading Update (0894B)
08 Junio 2021 - 1:00AM
UK Regulatory
TIDMDPH
RNS Number : 0894B
Dechra Pharmaceuticals PLC
08 June 2021
Tuesday, 8 June 2021
Dechra(R) Pharmaceuticals PLC
(Dechra, Group, Company)
Trading Update
The Board of Dechra is pleased to announce an update on trading
and outlook for the current financial year.
In our interim release on 22 February 2021, we reported on our
strong performance for the first seven months of the current
financial year. The Group has continued to benefit from strong
market fundamentals as well as lower Underlying Selling, General
and Administration (SG&A) costs as a result of COVID-19. This,
coupled with the completion of the UK pre-Brexit inventory unwind
and further easing of lockdown restrictions, means the Board is
increasingly confident that this strong performance will continue
for the rest of this financial year.
Consequently, the Group now expects full year revenue to be
ahead of current consensus expectations, with trading likely to be
distributed more evenly than previously guided between the first
and second halves of the financial year.
The Group plans to provide further details on its financial
results for the year ending 30 June 2021 in a pre-close trading
statement, expected to be issued on 12 July 2021.
Enquiries:
Dechra Pharmaceuticals PLC
Ian Page, Chief Executive Officer Office: +44 (0) 1606 814 730
Paul Sandland, Chief Financial Office: +44 (0) 1606 814 730
Officer
e-mail: corporate.enquiries@dechra.com
TooleyStreet Communications Ltd
Fiona Tooley, Director Mobile: +44 (0) 7785 703 523
e-mail: fiona@tooleystreet.com Office: +44 (0) 121 309 0099
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
relates products business. Our expertise is in the development,
manufacture marketing and sales of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products.
For more information, please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
Forward Looking Statement
This document may contain certain forward-looking statements.
The forward-looking statements reflect the knowledge and
information available to the Company during the preparation and up
to the publication of this document. By their very nature, these
statements depend upon circumstances and relate to events that may
occur in the future thereby involve a degree of uncertainty.
Therefore, nothing in this document should be construed as a profit
forecast by the Company.
Market Abuse Regulation (MAR)
The information contained within this announcement may
constitute inside information stipulated under the Market Abuse
Regulation (EU) No. 596/2014. Upon the publication of this
announcement via the Regulatory Information Service, this inside
information is now considered to be in the public domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTFRMRTMTJMBRB
(END) Dow Jones Newswires
June 08, 2021 02:00 ET (06:00 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024